Boom Or Bust? Where Will Bicara Therapeutics Inc (NASDAQ: BCAX) Stock Go Next?

During the last session, Bicara Therapeutics Inc (NASDAQ:BCAX)’s traded shares were 0.31 million. At the end of the trading day, the stock’s price was $24.01, reflecting an intraday gain of 1.39% or $0.33. The 52-week high for the BCAX share is $27.94, that puts it down -16.37 from that peak though still a striking 23.66% gain since the share price plummeted to a 52-week low of $18.33. The company’s market capitalization is $1.31B, and the average intraday trading volume over the past 10 days was 0.29 million shares, and the average trade volume was 512.97K shares over the past three months.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Bicara Therapeutics Inc (BCAX) registered a 1.39% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.39% in intraday trading to $24.01, hitting a weekly high. The stock’s 5-day price performance is 6.71%, and it has moved by 0.88% in 30 days. The short interest in Bicara Therapeutics Inc (NASDAQ:BCAX) is 0.66 million shares and it means that shorts have 3.09 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The consensus price target of analysts on Wall Street is $35, which implies an increase of 31.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $35 and $35 respectively. As a result, BCAX is trading at a discount of -45.77% off the target high and -45.77% off the low.

BCAX Dividends

Bicara Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.